MX384800B - Derivado de 3-desoxi y composiciones farmaceuticas del mismo. - Google Patents

Derivado de 3-desoxi y composiciones farmaceuticas del mismo.

Info

Publication number
MX384800B
MX384800B MX2018010983A MX2018010983A MX384800B MX 384800 B MX384800 B MX 384800B MX 2018010983 A MX2018010983 A MX 2018010983A MX 2018010983 A MX2018010983 A MX 2018010983A MX 384800 B MX384800 B MX 384800B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
deoxy derivative
compound
deoxy
derivative
Prior art date
Application number
MX2018010983A
Other languages
English (en)
Spanish (es)
Other versions
MX2018010983A (es
Inventor
Antimo Gioiello
Roberto Pellicciari
Original Assignee
Intercept Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc filed Critical Intercept Pharmaceuticals Inc
Publication of MX2018010983A publication Critical patent/MX2018010983A/es
Publication of MX384800B publication Critical patent/MX384800B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
MX2018010983A 2016-03-11 2017-03-07 Derivado de 3-desoxi y composiciones farmaceuticas del mismo. MX384800B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662306914P 2016-03-11 2016-03-11
PCT/US2017/021194 WO2017156024A1 (en) 2016-03-11 2017-03-07 3-desoxy derivative and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
MX2018010983A MX2018010983A (es) 2019-01-21
MX384800B true MX384800B (es) 2025-03-14

Family

ID=59787771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010983A MX384800B (es) 2016-03-11 2017-03-07 Derivado de 3-desoxi y composiciones farmaceuticas del mismo.

Country Status (20)

Country Link
US (3) US10815267B2 (enExample)
EP (1) EP3426348B1 (enExample)
JP (1) JP6892457B2 (enExample)
KR (1) KR102359191B1 (enExample)
CN (1) CN108883305B (enExample)
AR (1) AR107864A1 (enExample)
AU (1) AU2017229481B2 (enExample)
BR (1) BR112018068278B1 (enExample)
CA (1) CA3016875C (enExample)
EA (1) EA038632B1 (enExample)
ES (1) ES2874682T3 (enExample)
IL (1) IL261548B (enExample)
MX (1) MX384800B (enExample)
PH (1) PH12018501956A1 (enExample)
PL (1) PL3426348T3 (enExample)
PT (1) PT3426348T (enExample)
SG (1) SG11201807784SA (enExample)
SI (1) SI3426348T1 (enExample)
TW (1) TWI772289B (enExample)
WO (1) WO2017156024A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017009657A2 (pt) 2014-11-06 2018-01-23 Enanta Pharmaceuticals, Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
EP3359160B1 (en) 2015-10-07 2021-08-25 Intercept Pharmaceuticals, Inc. Farnesoid x receptor modulators
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
EA038632B1 (ru) 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
CA3201686A1 (en) * 2021-01-14 2022-07-21 Fabiola Terzi Method for treating chronic kidney diseases
WO2023288123A1 (en) 2021-07-16 2023-01-19 Interecept Pharmaceuticals, Inc. Methods and intermediates for the preparation of 3.alpha.,7.alpha.,11.beta.-trihydroxy-6.alpha.-ethyl-5.beta.-cholan-24-oic acid
KR20250006156A (ko) * 2022-04-21 2025-01-10 인터셉트 파마슈티컬즈, 인크. 파르네소이드 x 수용체 효능제의 용도
EP4547256A4 (en) * 2022-07-01 2026-07-08 Intercept Pharmaceuticals Inc METHODS FOR IMPROVING COGNITIVE IMPAIRMENT USING BILE ACID DERIVATIVES
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089316A2 (en) * 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
WO2012047495A2 (en) * 2010-09-27 2012-04-12 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
CN110041399B (zh) 2011-12-29 2023-12-12 诺沃—诺迪斯克有限公司 包含非成蛋白质性的氨基酸的二肽
CN105377870B (zh) * 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
SI3626725T1 (sl) 2014-05-29 2023-04-28 Bar Pharmaceuticals S.R.L. Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
EP3331896A4 (en) 2015-08-07 2019-08-14 Intercept Pharmaceuticals, Inc. PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF
EA038632B1 (ru) 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)

Also Published As

Publication number Publication date
TW201734031A (zh) 2017-10-01
AR107864A1 (es) 2018-06-13
TWI772289B (zh) 2022-08-01
EP3426348A1 (en) 2019-01-16
SG11201807784SA (en) 2018-10-30
PH12018501956A1 (en) 2019-06-17
PL3426348T3 (pl) 2022-01-03
ES2874682T3 (es) 2021-11-05
WO2017156024A1 (en) 2017-09-14
MX2018010983A (es) 2019-01-21
EA201892007A1 (ru) 2019-01-31
BR112018068278A2 (pt) 2019-04-02
CN108883305A (zh) 2018-11-23
SI3426348T1 (sl) 2021-11-30
EP3426348A4 (en) 2019-11-20
US11319337B2 (en) 2022-05-03
JP2019507781A (ja) 2019-03-22
CA3016875A1 (en) 2017-09-14
US20170260225A1 (en) 2017-09-14
CN108883305B (zh) 2021-03-16
US10815267B2 (en) 2020-10-27
EA038632B1 (ru) 2021-09-27
EP3426348B1 (en) 2021-05-05
NZ745980A (en) 2025-03-28
AU2017229481A1 (en) 2018-09-20
HK1259145A1 (zh) 2019-11-29
PT3426348T (pt) 2021-06-28
AU2017229481B2 (en) 2022-06-16
KR20180117702A (ko) 2018-10-29
KR102359191B1 (ko) 2022-02-04
IL261548B (en) 2021-02-28
BR112018068278B1 (pt) 2023-12-19
US20190002493A1 (en) 2019-01-03
CA3016875C (en) 2023-08-22
IL261548A (en) 2018-11-29
US20210101927A1 (en) 2021-04-08
JP6892457B2 (ja) 2021-06-23

Similar Documents

Publication Publication Date Title
MX2018010983A (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
PH12018500777A1 (en) Farnesoid x receptor modulators
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
MX391812B (es) Agonista fxr derivado de esteroides.
EA201690930A1 (ru) Композиции и способы модуляции фарнезоидных х-рецепторов
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
EA201691582A1 (ru) Новые фармацевтические препараты
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201992116A1 (ru) Фармацевтические составы флороглюцинола и триметилфлороглюцинола
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MD20170070A2 (ro) Derivaţi de chinazolină utilizaţi în tratamentul HIV
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
MX394123B (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
MX373603B (es) Activador de canales de kcnq2-5.
EA201791807A1 (ru) Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
MX388592B (es) Compuestos y metodos terapeuticos.